<?xml version="1.0" encoding="UTF-8"?>
<p id="Par59">Remdesivir is an adenosine nucleotide analog that is similar to tenofovir alafenamide - a nucleotide analog of adenosine 5-monophosphate - with antiviral activity against hepatitis B virus, HIV [
 <xref ref-type="bibr" rid="CR55">55</xref>], filoviruses, paramyxoviruses, and pathogenic coronaviruses, like SARS-CoV and MERS-CoV [
 <xref ref-type="bibr" rid="CR57">57</xref>]. In in-vitro research, the EC
 <sub>50</sub> of Remdesivir against SARS-COV-2 in Vero E6 cells was 0.77 μM and the EC
 <sub>90</sub> was 1.76 μM [
 <xref ref-type="bibr" rid="CR58">58</xref>]. The symptoms of a COVID-19 positive patient in Washington, USA treated with Remdesivir improved and no noticeable side effects were observed. Finally, 13 days after treatment with Remdesivir the result of real-time RT-PCR analysis from the oropharyngeal swab was negative for SARS-CoV-2 [
 <xref ref-type="bibr" rid="CR59">59</xref>].
</p>
